EVE HEALTH GROUP ORD

EVE Health (ASX: EVE) launches Libbo ED treatment and men’s health platform, unveiling an end-to-end digital pathway for nationwide access and scalable revenue.

EVE Health Group (ASX: EVE) has entered into a telehealth services agreement with hubMed to enhance the quality and continuity of care for patients using EVE’s therapeutic products including Dyspro for dysmenorrhoea and Libbo for erectile dysfunction.

EVE Health Group (ASX: EVE) has appointed its first dedicated medical science liaison (MSL) to lead national medical education and prescriber engagement programs across Australia.

EVE Health Group (ASX: EVE) has reached several key milestones in its transition to commercial operations, achieving first patient prescriptions of its Dyspro cannabinoid-based gummy and submitting the initial purchase order for Libbo, an oral dissolving film for erectile dysfunction.